Johnson & Johnson : 2026 First-Quarter Infographic & Earnings Presentation

Published: 2026-04-14 06:26:20 ET JNJ

Published on 04/14/2026 at 06:26 am EDT

Jst @uarter 2026 Results

/£ Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless

gJ5.4

billion

Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 11.2% or 7.4% operationally2. Stelara impacted results2 by -(920) basis points. Primary operational drivers:

$8.6

billion

Worldwide MedTech sales MedTech worldwide reported sales increased 7.7% or 4.6% operationally2 Primary operational drivers:

Joaquin Duato Chairman & Chief Executive Officer

Johnson & Johnson

focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque

psoriasis and VARIPULSE Pro in

@ Tremfya :^..DAY ZALE X CAPLYTAy

CAI?VYKTI"

Electrophysiology Abiomed

Shockwave

Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for

C PYBPEVANT + LAZCLUZE "

amivantamab-vmjW! .lazertinibi

SUSTENNA

Trauma

Wound Closure Contact Lenses & Healing

e»

shareholders. 57

Biosurgery

Surgical Vision

Johnson8iJohnson

For full financial data, non-GAAP reconciliations and c autionary statements, please refer to Johnson & Johnson's earnings release issued on April J4, 2026 avail abIe at https'//www investor jnj com/I'inanciaIs/quarterly results/default aspx ' Non GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the m ost comparable GAAP f inancial measures.

* Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning F arward-Looking Statements: This doc ument contains "forward-looking statements" as defined in the Private Securities Litigation Refo rm Act of 1995 reHarding future aperating and financial performance. You are cautioned not to rely on these Forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainti es that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Look ing Statements" inc luded in the Johnson & Johnson earnings release issued on April 14, 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Jo hnson & Johnson does not undertake to update any forward-look ing statement as a result of new information or future events or develop ments.

April 14, 2026

This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson.

Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website.

Strategic partnerships, collaborations & licensing arrangements

During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:

Oncology

IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences

Immunology

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics - Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc

Neuroscience

INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.

Other

PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan

Agenda

1 CEO Remarks

2 Sales performance and earnings review

3 Capital allocation and guidance update

4 Q&A

Joaquin Duato

Chairman and Chief Executive Officer

Joseph J. Wolk Executive Vice President, Chief Financial Officer

Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine

John Reed Executive Vice President, Innovative Medicine, R&D

Tim Schmid

Executive Vice President, Worldwide Chairman, MedTech

Darren Snellgrove Vice President, Investor Relations

Chairman and Chief Executive Officer

Q1 Earnings Summary

Six key businesses driving growth

operational sales growth1,2

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 7

2 Includes an approximate (540) basis point headwind from STELARA

Oncology

Immunology

Neuroscience

Innovative Medicine: 7.4% operational sales growth1,2

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

2 Includes an approximate (920) basis point headwind from STELARA 8

Note: Includes existing products and planned future launches

ICOTYD U.S. FDA approval brings new option

for first-line systemic treatment of plaque psoriasis

Immunology

First and only IL-23R targeted oral peptide to deliver complete skin clearance and favorable safety profile in a once-daily pill

Preferred first line systemic treatment for patients 12 and older with moderate to severe plaque psoriasis

No mandatory TB test or lab monitoring

Full launch occurred immediately on approval

Potential to revolutionize how psoriatic disease is treated

Oncology

Immunology

Neuroscience

Innovative Medicine: 7.4% operational sales growth1,2

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

2 Includes an approximate (920) basis point headwind from STELARA 10

Note: Includes existing products and planned future launches

VARIPULS Platform

Dua OL

SMARTTOUC SF Catheter

Shockwave Intravascular Impella® Heart OMNYPULS Lithotripsy System Pump Technology Catheter

Cardiovascular

Surgery

ETHICO 4000

Surgical Stapler

MONARC

Platform

OTTAV

Robotic Surgical System

Vision

TECNIS Odysse

TECNIS PureSe

l Energy THERMOCO

ACUVUE® OASYS 1-Day Family

MedTech: 4.6% operational sales growth1

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

Note: Includes existing products and planned future launches 11

Note: related to sales; excludes the impact of translational currency 12

Vice President, Investor Relations

1st Quarter 2026 sales

Dollars in billions

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded

% Change

Regional sales results

Q1 2026

Q1 2025

Reported

Operational1

U.S. $13.3

$12.3

8.3%

Europe

5.8

5.1

14.5

2.7

Western Hemisphere (ex U.S.)

1.3

1.2

10.8

2.5

Asia-Pacific, Africa

3.6

3.3

8.5

6.1

International

10.7

9.6

11.9

3.9

Worldwide (WW)

$24.1

$21.9

9.9%

6.4%

1st Quarter 2026 financial highlights

Dollars in billions, except EPS Reported %; Operational %1

$24.1

$21.9

Sales

GAAP earnings

$5.2

$11.0

GAAP EPS

$4.54

$2.14

Q1 2026 Q1 2025

9.9%; 6.4%1

Adjusted earnings2

$6.6 $6.7

(52.4)% (52.9)%

Adjusted EPS2

$2.70 $2.77

Q1 2026 Q1 2025

(1.4)%

Q1 2026 Q1 2025

(2.5)%; (7.2)%1

2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 15

Innovative Medicine highlights - 1st quarter 2026

Strong operational growth1 of 7.4% driven primarily by Oncology and Neuroscience

Stelara impacted results1 by ~(920) basis points

Reported: Operational1:

WW 11.2%, U.S. 9.6%, Int'l 13.4%

WW 7.4%, U.S. 9.6%, Int'l 4.3%

WW sales $MM

Key drivers of operational performance1

Oncology

DARZALEX increase primarily driven by strong share gains and market growth, partially offset by inventory dynamics

CARVYKTI increase driven by share gains and continued site expansion

TECVAYLI growth driven by launch uptake and share gains from expansion in the community setting and recent U.S. TECVAYLI + DARZALEX FASPRO approval

TALVEY growth driven by share gains from expansion in the community setting

RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains

ERLEADA increase driven by continued share gains in mCSPC and market growth

IMBRUVICA decrease driven by share loss due to continued competitive pressure and unfavorable patient mix

Immunology

TREMFYA growth due to share gains across all indications with significant IBD launch momentum and market growth

SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar competition, and unfavorable patient mix, partially offset by market growth

STELARA decline driven by the impact of biosimilar competition, increasing adoption of novel classes, and unfavorable patient mix

Neuroscience

SPRAVATO growth driven by continued increased physician and patient demand

CAPLYTA driven by strong continued momentum in the aMDD launch

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily driven by favorable patient mix

Other

UPTRAVI increase driven by market and share growth, partially offset by inventory dynamics

OPSUMIT/OPSYNVI growth driven by share gains, market growth, and favorable patient mix

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA increase driven by favorable patient mix

XARELTO decrease driven by continued share erosion

Reported growth ■ Operational growth1

Oncology

$6,973

22.8%, 17.8%

$15,426

11.2%, 7.4%

Immunology

$3,380

(8.8)%, (11.8)%

Neuroscience

$2,175

32.0%, 29.3%

Other

$2,899

2.1%, (0.9)%

Adjusted operational sales2: WW: 5.6%, U.S. 6.3%, Int'l 4.5%

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website

Note: Values may be rounded 16

MedTech highlights - 1st quarter 2026

Solid operational growth1 of 4.6% due to commercial execution and innovation

Reported: Operational1:

WW 7.7%, U.S. 5.9%, Int'l 9.7%

WW 4.6%, U.S. 5.9%, Int'l 3.2%

Key drivers of operational performance1

Cardiovascular

Electrophysiology: Increase driven by procedure growth, commercial execution, new product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL), and OUS inventory dynamics, partially offset by competitive pressures in PFA

Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP

Shockwave: Double digit growth driven by strong adoption of Coronary and Peripheral portfolios and new product launches (JAVELIN & E8)

Surgery

Advanced:

Biosurgery: ~ +5% growth driven by continued strength of the portfolio and commercial execution, partially offset by the impact of the surgery transformation program and VBP in China

Endocutters: ~ -3% due to competitive pressures and VBP in China

Energy: ~ +2% increase driven by new product launches, partially offset by VBP in China

General: Increase primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market expansion, offset by OUS tender timing

Vision

Contact Lenses/Other: Increase driven by strong performance of the ACUVUE OASYS 1-Day family of products and strategic price actions, partially offset by inventory dynamics OUS

Surgical: Growth driven by strength of recent product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by competitive pressures in the U.S.

Orthopaedics

Growth across all platforms primarily driven by new product launches and strong commercial execution:

Hips: Increase driven by new product launches (EMPHASYS)

Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull through related to the VELYS Robotic assisted solutions

Trauma: Growth driven by recently launched products (VOLT)

Spine, Sports & Other: New product innovations (TriAltis) and growth in shoulders, offset by competitive pressures and inventory dynamics

WW sales $MM

Reported growth ■ Operational growth1

Cardiovascular

$2,377

13.0%, 10.5%

Vision

$1,365

6.7%, 3.6%

$8,636

7.7%, 4.6%

Surgery

$2,511

4.8%, 1.2%

Orthopaedics

$2,383

6.3%, 3.2%

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website

Adjusted operational sales2: WW 4.7%, U.S. 6.1%, Int'l 3.2%

Note: Values may be rounded 17

Condensed consolidated statement of earnings

1st Quarter 2026

2026

2025

Increase (Decrease)

(Unaudited; Dollar and shares in millions except per share figures)

Amount

% to Sales

Amount

% to Sales

Sales to customers

$24,062

100.0

$21,893

100.0

9.9

Cost of products sold

8,106

33.7

7,357

33.6

10.2

Gross Profit

15,956

66.3

14,536

66.4

9.8

Selling, marketing and administrative expenses

6,034

25.1

5,112

23.3

18.0

Research and development expense

3,527

14.7

3,225

14.7

9.4

In-process research and development impairments

0.1

Interest (income) expense, net

0.2

(128)

(0.6)

Other (income) expense, net

294

1.2

(7,321)

(33.4)

Restructuring

0.1

Earnings before provision for taxes on income

5,990

24.9

13,631

62.3

(56.1)

Provision for taxes on income

755

3.1

2,632

12.1

(71.3)

Net Earnings

$5,235

21.8

$10,999

50.2

(52.4)

Net earnings per share (Diluted)

$2.14

$4.54

(52.9)

Average shares outstanding (Diluted)

2,445.2

2,423.8

Effective tax rate

12.6%

19.3%

Adjusted earnings before provision for taxes and net earnings1

Earnings before provision for taxes on income

$7,821

32.5

$8,011

36.6

(2.4)

Net earnings

$6,614

27.5

$6,706

30.6

(1.4)

Net earnings per share (Diluted)

$2.70

$2.77

(2.5)

Effective tax rate

15.4%

16.3%

Adjusted earnings before provision for taxes on income by segment

1st Quarter 2026

(Unaudited; Dollar in millions)

Innovative Medicine

2026

2025

Increase (Decrease)

Amount

% to Sales

Amount

% to Sales

Sales to customers

Cost of products sold

$15,426 100.0

3,617 23.4

$13,873 100.0

3,371 24.3

11.2

7.3

Gross Profit

$11,809 76.6

10,502 75.7

12.4

Selling, marketing and administrative expenses Research and development expense

Other segment items 1

2,918 18.9

2,813 18.2

(43) (0.2)

2,261 16.3

2,548 18.4

(204) (1.5)

29.1

10.4

Adjusted segment income before tax 2

$6,121 39.7

5,897 42.5

3.8

MedTech

2026

2025

Increase (Decrease)

Amount

% to Sales

Amount

% to Sales

Sales to customers

Cost of products sold

$8,636 100.0

3,192 37.0

8,020 100.0

2,795 34.8

7.7

14.2

Gross Profit

$5,444 63.0

5,225 65.2

4.2

Selling, marketing and administrative expenses Research and development expense

Other segment items 1

2,906 33.6

714 8.3

(98) (1.2)

2,656 33.1

671 8.4

(182) (2.2)

9.4

6.4

Adjusted segment income before tax 2

$1,922 22.3

2,080 25.9

(7.6)

Enterprise

2026

2025

Increase (Decrease)

Amount

% to Sales

Amount

% to Sales

Adjusted income before tax 2

$7,821 32.5

$8,011 36.6

(2.4)

1 Includes other Income and Expense

2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website

Executive Vice President, Chief Financial Officer

Dollars in billions Q1 2026

Capital allocation strategy

Higher priority

Lower priority

Capital allocation

Organic growth business needs

Free cash flow1

Investment in M&A

Competitive dividends

Share repurchases

Q1 2026:

$3.5B invested in R&D

$3.1B in dividends paid to shareholders

Cash and marketable

securities

$22.1

Debt

($55.0)

Net debt

($32.9)

Free cash flow1,2

~$1.5

Note: Values may be rounded

Priorities are clear and remain unchanged

1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment

2 Estimated as of April 14, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings

Note: Values may be rounded 21

2026 P&L guidance

Operational2 sales guidance of 6.4% and adjusted operational EPS2,4 at 5.7% (midpoints)

April 2026

January 2026

Comments

Adjusted operational sales1,2

5.6% - 6.6%

5.4% - 6.4%

Increasing midpoint to 6.1%

Operational sales2

$99.7B - $100.7B 5.9% - 6.9%

$99.5B - $100.5B 5.7% - 6.7%

Increasing midpoint by $0.2B to 6.4%

Estimated reported sales 3

$100.3B - $101.3B 6.5% - 7.5%

$100.0B - $101.0B 6.2% - 7.2%

Increasing midpoint by $0.3B to 7.0% Incremental FX impact of $0.1B or 0.1%

Adjusted pre-tax operating margin4,5

Increase of at least 50 bps

Maintaining

Net other income4

$1.0 - $1.2 billion

Maintaining

Net interest expense / (income)

$300 - $400 million

Maintaining

Effective tax rate4

17.5% - 18.5%

Maintaining

Adjusted EPS (operational)2,4

$11.30 - $11.50 4.7% - 6.7%

$11.28 - $11.48 4.5% - 6.5%

Increasing midpoint by $0.02 to 5.7%

Adjusted EPS (reported)3,4

$11.45 - $11.65 6.1% - 8.1%

$11.43 - $11.63 5.9% - 7.9%

Increasing midpoint by $0.02 to 7.1% Maintaining FX impact of $0.15 or 1.4%

1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items

2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses

3 Calculated using Euro Average Rate: April 2026 = $1.17 and January 2026 = $ 1.17

Note: Values may be rounded 22

Phasing Considerations

Anticipate fairly consistent operational1 sales growth in the first and second half; 53rd week impacts the second half

Expect more pronounced impact from newly launched products as the year progresses

Anticipate generic competition for OPSUMIT (second half in U.S.) and SIMPONI (first half in EU; potentially second half in U.S.)

Expect impact of voluntary agreement with the U.S. government to be evenly distributed throughout the year

Innovative Medicine

Expect continued acceleration of newly launched products as the year progresses with normalized seasonality

Surgery Transformation sales headwinds expected to increase through the year

Anticipate additional rounds of VBP in China throughout the year, heavier in the second half of the year

MedTech

P&L

Expect heavier investment in the first half of the year

Intra-Cellular benefit laps in Q2

Anticipate higher earnings per share growth in the second half of the year compared to the first half

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website

Anticipated 2026 milestones1 driving long-term value creation

Innovative Medicine MedTech

ICOTYDE in PsO TECVAYLI + DARZALEX in RRMM

TREMFYA in PsA SD TECVAYLI in RRMM INLEXZO in HR NMIBC

nipocalimab in WAIHA and SLE CAPLYTA in bipolar mania JNJ-4804

ERLEADA in LPC & HRPC

OTTAVA ETHIZIA

STSF Dual Energy Catheter C2 Aero Catheters TECNIS PureSee IOL

ATTUNE Hinge VOLT

MONARCH Urology VARIPULSE Pro

1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches

PsO: Psoriasis; RRMM: Relapsed/refractory multiple myeloma; PsA SD: Psoriatic arthritis structural damage; HR NMIBC: High-risk non-muscle invasive bladder cancer; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; LPC: Localized prostate cancer; HRPC: High-risk

prostate cancer; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens 24

Save the Date

Innovative Medicine

Oncology

Immunology

Neuroscience

Surgery

Cardiovascular

Vision

MedTech

Tuesday, December 8, 2026

Joaquin Duato

Chairman and Chief Executive Officer

Joseph J. Wolk Executive Vice President, Chief Financial Officer

Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine

John Reed Executive Vice President, Innovative Medicine, R&D

Tim Schmid

Executive Vice President, Worldwide Chairman, MedTech

Darren Snellgrove Vice President, Investor Relations

Slide footer goes here if required 27

Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026*

POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹

TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)

nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

US EU

ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)

Phase III

ICOTYDE (icotrokinra) Psoriasis (ICONIC-ADVANCE 1&2 Update)

ERLEADA (apalutamide)

Localized Prostate Cancer (ATLAS)

Phase I/ II

JNJ-4804 Co-antibody Therapy Ulcerative Colitis (DUET-UC)

ICOTYDE (icotrokinra)

CAPLYTA (lumateperone)

ERLEADA (apalutamide)

ICOTYDE (icotrokinra)

ERLEADA (apalutamide)

JNJ-4804 Co-antibody Therapy

Psoriasis (ICONIC)

Bipolar Mania

High Risk Prostate Cancer (PROTEUS)

Psoriasis (ICONIC-ASCEND)

High Risk Prostate Cancer (PROTEUS)

Crohn's Disease (DUET-CD)

AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

bleximenib

Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

icotrokinra

Psoriatic Arthritis (ICONIC-PsA)

TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

JNJ-4804 Co-antibody Therapy Psoriatic Arthritis (AFFINITY)

DARZALEX (daratumumab)

TALVEY (talquetamab)

ICOTYDE (icotrokinra)

TECVAYLI (teclistamab)

nipocalimab

Frontline multiple myeloma transplant ineligible (CEPHEUS)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

Psoriasis (ICONIC-TOTAL Update)

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC 9)

Systemic Lupus Erythematosus (JASMINE)

TECVAYLI (teclistamab)

CAPLYTA (lumateperone)

INLEXZO (gemcitabine intravesical delivery system)

bleximenib

Multiple Myeloma 1-3PLs (MajesTEC-3)

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

Bipolar Mania (ITI-007-452)

High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)

nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

JNJ-1887 sCD59

Geographic Atrophy (PARASOL)

INLEXZO (gemcitabine intravesical delivery system)

High Risk Non Muscle Invasive Bladder Cancer BCG

Experienced (SunRISe-5)

1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of April 14, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

Disclaimer

Johnson & Johnson published this content on April 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 14, 2026 at 10:25 UTC.